SCYNEXIS Completes SCY-247 Phase 1 and Plans Phase 2

SCYNEXIS said IV SCY-247 Phase 1 SAD/MAD studies showed tolerability and pharmacokinetics meeting efficacy targets at ≥50 mg once daily. A Phase 2 trial in invasive candidiasis is planned, subject to FDA agreement. BARDA funding of up to $214 million is available if milestones are met.